YM 758

Drug Profile

YM 758

Alternative Names: IFI-930A; YM 758 monophosphate; YM758

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Cardeus Pharmaceuticals
  • Class Antiarrhythmics; Ischaemic heart disorder therapies
  • Mechanism of Action Cyclic nucleotide-gated cation channel antagonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Atrial fibrillation

Most Recent Events

  • 31 Mar 2011 Phase-II clinical trials in Angina pectoris in Europe (PO)
  • 31 Mar 2011 Phase-II clinical trials in Atrial fibrillation in USA (PO)
  • 27 Dec 2007 Discontinued - Phase-II for Atrial fibrillation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top